Hepatic chemerin mRNA expression is reduced in human nonalcoholic steatohepatitis
Abstract
BACKGROUND: Chemerin is associated with insulin resistance and is expressed in the liver. Nonalcoholic fatty liver disease (NAFLD) is related to impaired insulin sensitivity, but studies evaluating hepatic and serum chemerin in NAFLD resulted in discordant data. MATERIALS AND METHODS: Chemerin mRNA was determined in the liver tissue obtained from 33 controls and 76 NAFLD patients. Chemerin serum levels were measured in a different cohort of patients with ultrasound-diagnosed NAFLD and the respective controls. Hepatic stellate cells and hepatocytes were exposed to selected metabolites and nuclear receptor agonists to study the regulation of chemerin. Effect of recombinant chemerin on hepatocyte released proteins was analysed. RESULTS: Hepatic chemerin expression was not related to BMI, gender, type 2 diabetes and hypertension. Chemerin mRNA did not correlate with steatosis and was negatively associated with inflammation, fibrosis and nonalcoholic steatohepatitis (NASH) score. Patients with NASH had lower chemerin mRNA compared to those with borderline NASH and controls. Factors with a role in NASH mostly did not regulate chemerin in the liver cells. Of note, liver X receptor agonist reduced chemerin protein. Serum chemerin was not changed in NAFLD. Levels positively correlated with age, waist-to-hip ratio, systolic blood pressure, serum FGF21 and lipocalin 2, and negatively with transferrin saturation. Chemerin induced FGF21 in supernatants of primary human hepatocytes. Hepcidin, a major regulator of iron homoeostasis and lipocalin 2, were not regulated by chemerin. CONCLUSION: Chemerin mRNA is reduced in the liver of NASH patients, and liver X receptor seems to have a role herein.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
High levels of chemerin are detected in obesity, metabolic syndrome, insulin resistance, and dyslipidemia.
“High levels of chemerin are detected in obesity, metabolic syndrome, insulin resistance, and dyslipidemia [72].”
From Adipokines, Myokines, and Hepatokines: Crosstalk and Metabolic Repercussions (2021) · cites this paper as [72]
Cites
NIH Image to ImageJ: 25 years of image analysis
Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012) · Nature Methods · doi:10.1038/nmeth.2089 · Cited by 64,638 · see citing works
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · see citing works
Chemerin: at the crossroads of inflammation and obesity
Ernst, M. C., & Sinal, C. J. (2010) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2010.08.001 · Cited by 428 · see citing works
NASH is an Infl ammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications
Farrell, G. C., Rooyen, D. M. V., Gan, L. T., & Chitturi, S. (2012) · Gut and Liver · doi:10.5009/gnl.2012.6.2.149 · Cited by 396 · see citing works
Sell, H., Laurencikiene, J., Taube, A., Eckardt, K., Cramer, A., Horrighs, A., Arner, P., & Eckel, J. (2009) · Diabetes · doi:10.2337/db09-0277 · Cited by 389 · see citing works
Synthetic chemerin-derived peptides suppress inflammation through ChemR23
Cash, J. L., Hart, R., Russ, A., Dixon, J. P. C., Colledge, W. H., Doran, J., Hendrick, A. G., Carlton, M. B. L., & Greaves, D. R. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071601 · Cited by 372 · see citing works
Chemerin Activation by Serine Proteases of the Coagulation, Fibrinolytic, and Inflammatory Cascades
Zabel, B. A., Allen, S. J., Kulig, P., Allen, J. A., Cichy, J., Handel, T. M., & Butcher, E. C. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504868200 · Cited by 369 · see citing works
Pathological Features of Fatty Liver Disease
Yeh, M. M., & Brunt, E. M. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.07.056 · Cited by 339 · see citing works
Preiss, D., & Sattar, N. A. (2008) · Clinical Science · doi:10.1042/cs20070402 · Cited by 292 · see citing works
Higuchi, N., Kato, M., Shundo, Y., Tajiri, H., Tanaka, M., Yamashita, N., Kohjima, M., Kotoh, K., Nakamuta, M., Takayanagi, R., et al. (2008) · Hepatology Research · doi:10.1111/j.1872-034x.2008.00382.x · Cited by 285 · see citing works
Towards an integrative approach to understanding the role of chemerin in human health and disease
Rourke, J. L., Dranse, H. J., & Sinal, C. J. (2012) · Obesity Reviews · doi:10.1111/obr.12009 · Cited by 282 · see citing works
Nuclear receptors and nonalcoholic fatty liver disease
Cave, M. C., Clair, H. B., Hardesty, J., Falkner, K. C., Feng, W., Clark, B. J., Sidey, J., Shi, H., Aqel, B. A., McClain, C. J., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2016.03.002 · Cited by 280 · see citing works
Adiponectin, a key adipokine in obesity related liver diseases.
Buechler, C., Wanninger, J., & Neumeier, M. (2011) · PubMed Central · doi:10.3748/wjg.v17.i23.2801 · Cited by 261 · see citing works
Chemerin Exacerbates Glucose Intolerance in Mouse Models of Obesity and Diabetes
Ernst, M. C., Issa, M. E., Goralski, K. B., & Sinal, C. J. (2010) · Endocrinology · doi:10.1210/en.2009-1098 · Cited by 260 · see citing works
Luangsay, S., Wittamer, V., Bondue, B., Henau, O. D., Rouger, L., Brait, M., Franssen, J.-D., de Nadaı̈, P., Huaux, F., & Parmentier, M. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901037 · Cited by 256 · see citing works
Insulin and Metformin Regulate Circulating and Adipose Tissue Chemerin
Tan, B. K., Chen, J., Syed, F., Adya, R., Kaur, J., Heutling, D., Lewandowski, K. C., O’Hare, J. P., Lehnert, H., & Randeva, H. S. (2009) · Diabetes · doi:10.2337/db08-1528 · Cited by 195 · see citing works
Xu, M., Feng, D., Wu, H., Wang, H., Chan, Y. R., Kolls, J. K., Borregaard, N., Porse, B. T., Berger, T., Mak, T. W., et al. (2014) · Hepatology · doi:10.1002/hep.27447 · Cited by 179 · see citing works
Kapil, S., Duseja, A. K., Sharma, B. K., Singla, B., Chakraborti, A., Das, A., Ray, P., Dhiman, R. K., & Chawla, Y. K. (2015) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13058 · Cited by 172 · see citing works
Adiponectin, a key adipokine in obesity related liver diseases
Christa, Buechler, Josef, Wanninger, Markus, M. L., & Neumeier (2011) · Acta Scientiarum Naturalium Universitatis Sunyatseni · Cited by 167 · see citing works
Adipocytokines and liver disease
Kamada, Y., Takehara, T., & Hayashi, N. (2008) · Journal of Gastroenterology · doi:10.1007/s00535-008-2213-6 · Cited by 153 · see citing works
Lipocalin 2 Deficiency Dysregulates Iron Homeostasis and Exacerbates Endotoxin-Induced Sepsis
Srinivasan, G., Aitken, J. D., Zhang, B., Carvalho, F. A., Chassaing, B., Shashidharamurthy, R., Borregaard, N., Jones, D. P., Gewirtz, A. T., & Vijay–Kumar, M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200892 · Cited by 137 · see citing works
Bauer, S., Wanninger, J., Schmidhofer, S., Weigert, J., Neumeier, M., Dorn, C., Hellerbrand, C., Zimara, N., Schäffler, A., Aslanidis, C., et al. (2010) · Endocrinology · doi:10.1210/en.2010-1157 · Cited by 134 · see citing works
Yilmaz, Y. N., Yönal, O., Kurt, R., Alahdab, Y. Ö., Eren, F., Ozdogan, O. C., Çelikel, Ç., İmeryüz, N., Kalaycı, C., & Avşar, E. (2010) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2010.516452 · Cited by 131 · see citing works
Zhang, F., Yu, L., Lin, X., Cheng, P., He, L., Li, X., Lu, X., Tan, Y., Yang, H., Cai, L., et al. (2015) · Molecular Endocrinology · doi:10.1210/me.2015-1155 · Cited by 130 · see citing works
Serum chemerin and vaspin in non-alcoholic fatty liver disease
Kukla, M., Żwirska-Korczala, K., Hartleb, M., Waluga, M., Chwist, A., Kajor, M., Ciupińska-Kajor, M., Berdowska, A., Woźniak-Grygiel, E., & Bułdak, R. J. (2010) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365520903443852 · Cited by 121 · see citing works
Becker, M., Rabe, K., Lebherz, C., Zugwurst, J., Göke, B., Parhofer, K. G., Lehrke, M., & Broedl, U. C. (2010) · Diabetes · doi:10.2337/db10-0362 · Cited by 108 · see citing works
Chemerin is highly expressed in hepatocytes and is induced in non-alcoholic steatohepatitis liver
Krautbauer, S., Wanninger, J., Eisinger, K., Hader, Y., Beck, M., Kopp, A., Schmid, A., Weiß, T. S., Dorn, C., & Buechler, C. (2013) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2013.07.009 · Cited by 95 · see citing works
Practice patterns in NAFLD and NASH: real life differs from published guidelines
Rinella, M. E., Lominadze, Z., Loomba, R. S., Charlton, M., Neuschwander‐Tetri, B. A., Caldwell, S. H., Kowdley, K. V., & Harrison, S. A. (2015) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x15611581 · Cited by 95 · see citing works
Li, Y., Shi, B., & Li, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113915 · Cited by 90 · see citing works
Elevated hepatic chemerin mRNA expression in human non-alcoholic fatty liver disease
Döcke, S., Lock, J. F., Birkenfeld, A. L., Hoppe, S., Lieske, S., Rieger, A., Raschzok, N., Sauer, I. M., Florian, S., Osterhoff, M. A., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0112 · Cited by 87 · see citing works
Systematic review: Preventive and therapeutic applications of metformin in liver disease
Bhat, A. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i12.1652 · Cited by 86 · see citing works
Oxidative stress mediates chemerin-induced autophagy in endothelial cells
Shen, W., Tian, C., Chen, H., Yang, Y., Zhu, D., Gao, P., & Liu, J. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.11.011 · Cited by 83 · see citing works
Does Hepatic Steatosis Affect Drug Metabolizing Enzymes in the Liver?
Buechler, C., & Weiß, T. S. (2011) · Current Drug Metabolism · doi:10.2174/138920011794520035 · Cited by 63 · see citing works
Association of chemerin levels in synovial fluid with the severity of knee osteoarthritis
Huang, K., Du, G., Li, L., Liang, H.-S., & Zhang, B. (2012) · Biomarkers · doi:10.3109/1354750x.2011.634028 · Cited by 62 · see citing works
Chenodeoxycholic acid, an endogenous FXR ligand alters adipokines and reverses insulin resistance
Shihabudeen, M. S., Roy, D., James, J., & Thirumurugan, K. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.07.012 · Cited by 60 · see citing works
Wolfs, M. G. M., Gruben, N., Rensen, S. S., Verdam, F. J., Greve, J.-W. M., Driessen, A. L. C., Wijmenga, C., Buurman, W. A., Franke, L., Scheja, L., et al. (2015) · Nutrition and Diabetes · doi:10.1038/nutd.2014.43 · Cited by 52 · see citing works
Deng, Y., Wang, H., Lu, Y., Liu, S., Zhang, Q., Huang, J. V., Zhu, R., Yang, J., Zhang, R., Zhang, D., et al. (2013) · Endocrinology · doi:10.1210/en.2012-2126 · Cited by 50 · see citing works
Wanninger, J., Neumeier, M., Hellerbrand, C., Schacherer, D., Bauer, S., Weiß, T. S., Huber, H., Schäffler, A., Aslanidis, C., Schölmerich, J., et al. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.11.001 · Cited by 44 · see citing works
Human parenchymal and non-parenchymal liver cell isolation, culture and characterization
Damm, G., Pfeiffer, E., Burkhardt, B., Vermehren, J., Nüssler, A. K., & Weiss, T. S. (2013) · Hepatology International · doi:10.1007/s12072-013-9475-7 · Cited by 36 · see citing works
Serum lipocalin-2, cathepsin S and chemerin levels and nonalcoholic fatty liver disease
Ye, Z., Wang, S., Yang, Z., He, M., Zhang, S., Zhang, W., Wen, J., Li, Q., Huang, Y., Wang, X., et al. (2014) · Molecular Biology Reports · doi:10.1007/s11033-013-2977-5 · Cited by 35 · see citing works
Zhang, R., Liu, S., Guo, B., Chang, L., & Li, Y. (2014) · Pharmacology · doi:10.1159/000369171 · Cited by 33 · see citing works
Reduced serum chemerin in patients with more severe liver cirrhosis
Eisinger, K., Krautbauer, S., Wiest, R., Weiß, T. S., & Buechler, C. (2015) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2015.01.010 · Cited by 30 · see citing works
Annexin A6 protein is downregulated in human hepatocellular carcinoma
Haberl, E. M., Rein‐Fischboeck, L., Pohl, R., Wanninger, J., Hoy, A. J., Grewal, T., Eisinger, K., Krautbauer, S., Liebisch, G., Weiß, T. S., et al. (2016) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-016-2735-9 · Cited by 30 · see citing works
Małyszko, J., Tesař, V., & Macdougall, I. C. (2010) · Kidney & Blood Pressure Research · doi:10.1159/000315436 · Cited by 28 · see citing works
Dranse, H. J., Muruganandan, S., Fawcett, J. P., & Sinal, C. J. (2016) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.07.017 · Cited by 25 · see citing works
Buechler, C. (2014) · University of Regensburg Publication Server (University of Regensburg) · doi:10.5283/epub.31597 · Cited by 24 · see citing works
Yoneda, M., Thomas, E., Sumida, Y., Imajo, K., Eguchi, Y., Hyogo, H., Fujii, H., Ono, M., Kawaguchi, T., & Schiff, E. R. (2014) · Hepatology Research · doi:10.1111/hepr.12327 · Cited by 21 · see citing works
Bauer, S., Weiß, T. S., Wiest, R., Schacherer, D., Hellerbrand, C., Farkas, S. A., Scherer, M. N., Ritter, M., Schmitz, G., Schäffler, A., et al. (2011) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2011.07.005 · Cited by 19 · see citing works
HepaticChemerinandChemokine-Like Receptor 1Expression in Patients with Chronic Hepatitis C
Kukla, M., Adamek, B., Waluga, M., Zalewska−Ziob, M., Kasperczyk, J., Gabriel, A., Mazur, W., Sobala‐Szczygieł, B., Bułdak, R. J., Zajęcki, W., et al. (2014) · BioMed Research International · doi:10.1155/2014/517820 · Cited by 18 · see citing works
Monteiro, J. M., Monteiro, G. B. M., Caroli‐Bottino, A., & Pannain, V. L. (2014) · Analytical Cellular Pathology · doi:10.1155/2014/526979 · Cited by 15 · see citing works
Xianghua, Z., Fudun, S., Liang, L., Jiang, D., Li, X., Ai-li, S., Zhe, P., Nengjun, L., Zhang, L., & Lou, F. (2015) · Clinical Laboratory · doi:10.7754/clin.lab.2015.150211 · Cited by 15 · see citing works
Rein‐Fischboeck, L., Krautbauer, S., Eisinger, K., Pohl, R., Haberl, E. M., Weiß, T. S., & Buechler, C. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.09.149 · Cited by 14 · see citing works
Haberl, E. M., Pohl, R., Rein‐Fischboeck, L., Schacherer, D., Eisinger, K., Wiest, R., Krautbauer, S., & Buechler, C. (2016) · Cytokine · doi:10.1016/j.cyto.2016.06.004 · Cited by 11 · see citing works
Neumann, M., Haberl, E. M., Rein‐Fischboeck, L., Krautbauer, S., Eisinger, K., Aslanidis, C., Pohl, R., Weiß, T. S., & Buechler, C. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17081335 · Cited by 10 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Adipokines and Non-Alcoholic Fatty Liver Disease: Multiple Interactions
Adolph, T. E., Grander, C., Grabherr, F., & Tilg, H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081649 · Cited by 243 · see citing works
Adipokines, Myokines, and Hepatokines: Crosstalk and Metabolic Repercussions
de Oliveira dos Santos, A. R., de Oliveira Zanuso, B., Miola, V. F. B., Barbalho, S. M., Santos Bueno, P. C., Flato, U. A. P., Detregiachi, C. R. P., Buchaim, D. V., Buchaim, R. L., Tofano, R. J., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052639 · Cited by 189 · see citing works
Chemerin Isoforms and Activity in Obesity
Buechler, C., Feder, S., Haberl, E. M., & Aslanidis, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051128 · Cited by 170 · see citing works
Hepatokines and adipokines in NASH-related hepatocellular carcinoma
Kücükoglu, Ö., Sowa, J., Mazzolini, G. D., Syn, W., & Canbay, A. E. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.10.030 · Cited by 114 · see citing works
Francisco, V., Sanz, M., Real, J. T., Marqués, P., Capuozzo, M., Eldjoudi, D. A., & Gualillo, O. (2022) · Biology · doi:10.3390/biology11081237 · Cited by 80 · see citing works
Gao, D., Jiao, J., Wang, Z., Huang, X., Ni, X., Fang, S., Zhou, Q., Zhu, X., Sun, L., Yang, Z. R., et al. (2022) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2022.04.002 · Cited by 50 · see citing works
Obesity linking to hepatocellular carcinoma: A global view
Gan, L., Liu, Z., & Sun, C. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.12.006 · Cited by 46 · see citing works
Fibroblast growth factor 21 in lipid metabolism and non-alcoholic fatty liver disease
Su, X., Kong, Y., & Peng, D. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.08.005 · Cited by 40 · see citing works
Chemerin in immune response and gastrointestinal pathophysiology
Jacenik, D., & Fichna, J. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.02.008 · Cited by 39 · see citing works
An, X., Liu, J., Li, Y., Dou, Z., Li, N., Suo, Y., Ma, Y., Sun, M., Tian, Z., & Xu, L. (2020) · Peptides · doi:10.1016/j.peptides.2020.170422 · Cited by 32 · see citing works
Iacob, S. A., & Iacob, D. G. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.814209 · Cited by 28 · see citing works
Horn, P., von Loeffelholz, C., Forkert, F., Stengel, S., Reuken, P. A., Aschenbach, R., Stallmach, A., & Bruns, T. (2018) · Scientific Reports · doi:10.1038/s41598-018-27543-6 · Cited by 24 · see citing works
Chou, H., Teng, M., Hsu, L., Er, L., Wu, S., & Ko, Y. (2021) · Clinical Endocrinology · doi:10.1111/cen.14441 · Cited by 22 · see citing works
Ren, Q., Wang, H., Zeng, Y., Xia, F., Wang, M., Li, D., Huang, W., & Xu, Y. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01637-7 · Cited by 23 · see citing works
Lavis, P., Morra, S., Cano, C. O., Albayrak, N., Corbière, V., Olislagers, V., Dauby, N., del Mármol, V., Marchant, A., Decaestecker, C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.941663 · Cited by 22 · see citing works
Haberl, E. M., Feder, S., Pohl, R., Rein‐Fischboeck, L., Dürholz, K., Eichelberger, L., Wanninger, J., Weiß, T. S., & Buechler, C. (2020) · Cancers · doi:10.3390/cancers12102967 · Cited by 18 · see citing works
Moodi, M., Tavakoli, T., & Tahergorabi, Z. (2021) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_266_20 · Cited by 17 · see citing works
Zimny, S., Pohl, R., Rein‐Fischboeck, L., Haberl, E. M., Krautbauer, S., Weiß, T. S., & Buechler, C. (2017) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2017.06.001 · Cited by 17 · see citing works
Pohl, R., Feder, S., Haberl, E. M., Rein‐Fischboeck, L., Weiß, T. S., Spirk, M., Bruckmann, A., McMullen, N. M., Sinal, C. J., & Buechler, C. (2022) · Biomedicines · doi:10.3390/biomedicines10010132 · Cited by 16 · see citing works
You, D., Lyn‐Cook, L. E., Gatti, D. M., Bell, N., Mayeux, P. R., James, L. P., Mattes, W. B., Larson, G. J., & Harrill, A. H. (2020) · Toxicological Sciences · doi:10.1093/toxsci/kfaa037 · Cited by 15 · see citing works
Schedlbauer, C., Blaue, D., Gericke, M. T., Blüher, M., Starzonek, J., Gittel, C., Brehm, W., & Vervuert, I. (2019) · PeerJ · doi:10.7717/peerj.7069 · Cited by 12 · see citing works
Lin, X., Qu, J., Yin, L., Wang, R., & Wang, X. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2023.159409 · Cited by 11 · see citing works
Contribution of organokines in the development of NAFLD/NASH associated hepatocellular carcinoma
Vachher, M., Bansal, S., Kumar, B., Yadav, S., Arora, T. K., Wali, N. M., & Burman, A. (2022) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30252 · Cited by 11 · see citing works
Associations of circulating chemerin and adiponectin concentrations with hepatic steatosis
Levin, L.-M., Völzke, H., Lerch, M. M., Kühn, J., Nauck, M. A., Friedrich, N., & Zylla, S. (2019) · Endocrine Connections · doi:10.1530/ec-19-0300 · Cited by 11 · see citing works
Circulating fibroblast growth factor 21 in patients with liver cirrhosis
Krautbauer, S., Rein‐Fischboeck, L., Haberl, E. M., Pohl, R., Wiest, R., & Buechler, C. (2017) · Clinical and Experimental Medicine · doi:10.1007/s10238-017-0468-z · Cited by 11 · see citing works
Karamfilova, V., Assyov, Y. S., Nedeva, I., Gateva, A., Ivanova, I. D., Cherkezov, N., Mateva, L., & Kamenov, Z. A. (2021) · The Turkish Journal of Gastroenterology · doi:10.5152/tjg.2021.201165 · Cited by 10 · see citing works
Serum Chemerin Does Not Differentiate Colorectal Liver Metastases from Hepatocellular Carcinoma
Feder, S., Kandulski, A., Schacherer, D., Weiß, T. S., & Buechler, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20163919 · Cited by 9 · see citing works
Chemerin As A Non-Invasive Serum Marker for Non-Alcoholic Fatty Liver Disease
Mohamed, G. A., Salama, M. M., Bayoumy, E., Mohamed, A., Ibrahim, W. A., Elshafie, A. I., & Abdallah, M. (2021) · The Egyptian Journal of Hospital Medicine · doi:10.21608/ejhm.2021.177253 · Cited by 5 · see citing works
Rastkar, M., Nikniaz, L., Farhangi, M. A., & Nikniaz, Z. (2023) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-023-01187-4 · Cited by 5 · see citing works
Serum Adiponectin Levels Do Not Distinguish Primary from Metastatic Liver Tumors
Feder, S., Kandulski, A., Schacherer, D., Weiß, T. S., & Buechler, C. (2019) · Anticancer Research · doi:10.21873/anticanres.13935 · Cited by 4 · see citing works
Rein‐Fischboeck, L., Pohl, R., Haberl, E. M., Weiß, T. S., & Buechler, C. (2017) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2017.09.005 · Cited by 3 · see citing works
Chemerin and the Gut: From Inflammation to Cancer
Pljakic, E., Delic, E., Corovic, I. F., Maksić, M., Radojević, D., Stanisavljević, I., Mladenović, V., Nikolić, T., Suljic, L., Ćorović, E., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13112618 · Cited by 2 · see citing works
Xiao, Z., Chen, J., Fan, X., Zhao, W., Chu, C., & Zhang, J. V. (2024) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2024.0152 · Cited by 2 · see citing works
Research update for articles published in EJCI in 2014
Agra, R. M., Al‐Daghri, N. M., Badimón, L., Bodı́, V., Carbone, F., Chen, M., Cubedo, J., Dullaart, R. P. F., Eiras-Penas, S., García‐Monzón, C., et al. (2016) · European Journal of Clinical Investigation · doi:10.1111/eci.12671 · Cited by 2 · see citing works
A Polymorphism in the FGF21 Gene is a Novel Risk Variant for Metabolic-Associated Steatohepatitis
Elsayed, A. (2020) · The Sydney eScholarship Repository (The University of Sydney) · Cited by 2 · see citing works
Pavel, V., Amend, P., Schmidtner, N., Utrata, A., Birner, C., Schmid, S. A., Krautbauer, S., Müller, M., Mester, P., & Buechler, C. (2024) · Biomedicines · doi:10.3390/biomedicines12092099 · Cited by 1 · see citing works
Research update for articles published in EJCI in 2017
Arellano‐Orden, E., Bacopoulou, F., Băicuş, C., Bonfrate, L., Broadbent, J., Buechler, C., Carbone, F., Charmandari, E., Davis, G. R., Dullaart, R. P. F., et al. (2019) · European Journal of Clinical Investigation · doi:10.1111/eci.13163 · Cited by 1 · see citing works
Cross-talk between hepatokines as Liver indused-exercise factors and organokinesPreprint
Rad, R. S. (2023) · Research Square · doi:10.21203/rs.3.rs-3734627/v1
Organokinler ve Biyokimyasal Etkileri
İlhan, A., & Kökbaş, U. (2024) · Arşiv Kaynak Tarama Dergisi · doi:10.17827/aktd.1378295
Ren, Q., Wang, H., Zeng, Y., Fang, X., Wang, M., Li, D., Huang, W., & Xu, Y. (2022) · Figshare · doi:10.6084/m9.figshare.19298438
Ren, Q., Wang, H., Zeng, Y., Fang, X., Wang, M., Li, D., Huang, W., & Xu, Y. (2022) · Figshare · doi:10.6084/m9.figshare.19298432
Progress on Chemokine-Like Receptor 1 in Metabolic Diseases
龙, 均. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.15123387
Tissue-Specific Chemerin in Atherosclerosis
Chen, M., Li, Y., Linling, F., & Liu, L. (2026) · Biomolecules · doi:10.3390/biom16091327
Gong, Z., Jia, H., Zhang, H., Yan, X., Xiang, Z., & Wan, Q. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1927210
- Authors
- Pohl, R., Haberl, E. M., Rein‐Fischboeck, L., Zimny, S., Neumann, M., Aslanidis, C., Schacherer, D., Krautbauer, S., Eisinger, K., Weiss, T. S., & Buechler, C.
- Affiliations
- University Hospital Regensburg (DE)
- Corresponding author
- Buechler, Christa
- Venue
- European Journal of Clinical Investigation
- Publisher
- Wiley
- Published
- 2016-11-21
- Volume
- 47
- Issue
- 1
- Pages
- 7-18
- ISSN
- 0014-2972 (ISSN-L)
- 1365-2362
- OpenAlex
- W2548217573
- Cited by
- 45
- References
- 54
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 3 · 2023: 3 · 2022: 9 · 2021: 5 · 2020: 6 · 2019: 8 · 2018: 2 · 2017: 4 · 2016: 1
- FWCI
- 4.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Clinical Investigation (publishedVersion)
- PubMed (publishedVersion)
- University of Regensburg Publication Server (University of Regensburg) (submittedVersion)
- Funders
- Deutsche Forschungsgemeinschaft (BU 1141/7‐1)
- Topics
- Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- chemerin, nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, hepatic gene expression, liver X receptor, insulin resistance, liver inflammation, liver fibrosis, FGF21, neutrophil gelatinase-associated lipocalin, hepcidin, iron homeostasis, hepatocytes, hepatic stellate cells
- MeSH terms
- Lipocalin-2, Liver X Receptors, Rosiglitazone, Benzenesulfonamides, Receptor, Farnesoid X-Activated, Adult, Aged, Aged, 80 and over, Cell Line, Cells, Cultured, Diabetes Mellitus, Type 2, Female, Fibroblast Growth Factors, Fluorocarbons, Humans, Hydrocarbons, Fluorinated, Hypertension, Hypoglycemic Agents, Insulin Resistance, Liver, Male, Middle Aged, Recombinant Proteins, RNA, Messenger, Severity of Illness Index, Sulfonamides, Comorbidity, Body Mass Index, Case-Control Studies, Cytokines, Receptors, Cytoplasmic and Nuclear, Chemokines, Reverse Transcriptase Polymerase Chain Reaction, Leptin, Hepatocytes, Intercellular Signaling Peptides and Proteins, Thiazolidinediones, Waist-Hip Ratio, Hepatic Stellate Cells, Young Adult, Hep G2 Cells, Real-Time Polymerase Chain Reaction, Hepcidins, Non-alcoholic Fatty Liver Disease, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
